MXPA06002846A - Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa. - Google Patents
Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa.Info
- Publication number
- MXPA06002846A MXPA06002846A MXPA06002846A MXPA06002846A MXPA06002846A MX PA06002846 A MXPA06002846 A MX PA06002846A MX PA06002846 A MXPA06002846 A MX PA06002846A MX PA06002846 A MXPA06002846 A MX PA06002846A MX PA06002846 A MXPA06002846 A MX PA06002846A
- Authority
- MX
- Mexico
- Prior art keywords
- cyano
- chloro
- quinolinyl
- butenamide
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66227303A | 2003-09-15 | 2003-09-15 | |
PCT/US2003/032612 WO2005034955A1 (en) | 2003-09-15 | 2003-10-15 | Substituted quinolines as protein tyrosine kinase enzyme inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06002846A true MXPA06002846A (es) | 2006-06-14 |
Family
ID=34435322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06002846A MXPA06002846A (es) | 2003-09-15 | 2003-10-15 | Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1670473A1 (ru) |
AU (1) | AU2003304497B2 (ru) |
BR (1) | BR0318503A (ru) |
CA (1) | CA2537978C (ru) |
MX (1) | MXPA06002846A (ru) |
UA (1) | UA85394C2 (ru) |
WO (1) | WO2005034955A1 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
EP1883631A1 (en) * | 2005-05-25 | 2008-02-06 | Wyeth | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof |
EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
RS51483B (en) * | 2006-04-14 | 2011-04-30 | Astrazeneca Ab | 4-ANILOXOQINOLINE-3-CARBOXamide KAO INHIBITOR CSF-1R Kinase |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
NZ616613A (en) | 2008-06-17 | 2015-05-29 | Wyeth Llc | Antineoplastic combinations containing hki-272 and vinorelbine |
AU2009279771B2 (en) | 2008-08-04 | 2015-05-14 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
CN101723854A (zh) | 2008-10-24 | 2010-06-09 | 上海特化医药科技有限公司 | 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体 |
HUE061640T2 (hu) | 2009-04-06 | 2023-07-28 | Wyeth Llc | Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával |
GB0922302D0 (en) * | 2009-12-22 | 2010-02-03 | Imp Innovations Ltd | Compounds |
CN102146084B (zh) * | 2010-02-04 | 2014-05-07 | 江苏恒瑞医药股份有限公司 | 3-氰基-6-氨基喹啉类衍生物、其制备方法及其在医药上的应用 |
EP2688565A1 (en) | 2011-03-23 | 2014-01-29 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
CN102718679B (zh) * | 2011-03-30 | 2016-06-08 | 北京万全阳光医药科技有限公司 | 一种诺那替尼关键中间体的制备方法 |
CN102731395B (zh) * | 2011-04-15 | 2015-02-04 | 中国科学院上海药物研究所 | 抗肿瘤药物来那替尼的中间体及其制备与应用 |
US9085540B2 (en) | 2012-01-17 | 2015-07-21 | Astellas Pharma Inc. | Pyrazinecarboxamide compound |
CN104926669A (zh) * | 2014-03-18 | 2015-09-23 | 江苏豪森医药集团连云港宏创医药有限公司 | 反式-4-二甲基胺基巴豆酸盐酸盐的制备方法 |
US11578074B2 (en) | 2017-09-01 | 2023-02-14 | Shanghai Pharmaceuticals Holding Cd., Ltd. | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application |
CN110357854A (zh) * | 2018-03-26 | 2019-10-22 | 江苏创诺制药有限公司 | 一种来那替尼的制备方法 |
CN111848581B (zh) * | 2020-08-19 | 2021-08-10 | 昆明学院 | 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法 |
CN111943933B (zh) * | 2020-09-02 | 2021-05-28 | 重庆医科大学 | 一种来那替尼杂质d的制备方法 |
CN111995618B (zh) * | 2020-09-02 | 2021-06-11 | 重庆医科大学 | 一种来那替尼杂质g的制备方法 |
CN114920695B (zh) * | 2022-06-29 | 2023-06-20 | 深圳大学总医院 | 一种喹唑啉衍生物及其制备方法、药物组合物和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
RU2309150C2 (ru) * | 2001-11-27 | 2007-10-27 | Уайт Холдингз Корпорейшн | 3-цианохинолины в качестве ингибиторов egf-r и her2 киназ |
-
2003
- 2003-10-15 CA CA2537978A patent/CA2537978C/en not_active Expired - Lifetime
- 2003-10-15 MX MXPA06002846A patent/MXPA06002846A/es active IP Right Grant
- 2003-10-15 EP EP03818857A patent/EP1670473A1/en not_active Withdrawn
- 2003-10-15 AU AU2003304497A patent/AU2003304497B2/en not_active Ceased
- 2003-10-15 UA UAA200604144A patent/UA85394C2/ru unknown
- 2003-10-15 WO PCT/US2003/032612 patent/WO2005034955A1/en active Application Filing
- 2003-10-15 BR BRPI0318503-6A patent/BR0318503A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2537978C (en) | 2011-08-02 |
EP1670473A1 (en) | 2006-06-21 |
AU2003304497B2 (en) | 2010-06-24 |
AU2003304497A1 (en) | 2005-04-27 |
CA2537978A1 (en) | 2005-04-21 |
WO2005034955A1 (en) | 2005-04-21 |
UA85394C2 (ru) | 2009-01-26 |
BR0318503A (pt) | 2006-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7399865B2 (en) | Protein tyrosine kinase enzyme inhibitors | |
MXPA06002846A (es) | Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa. | |
EP1448531B1 (en) | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases | |
KR101540421B1 (ko) | 혈관신생 저해제로서 스피로 치환된 화합물 | |
US6002008A (en) | Substituted 3-cyano quinolines | |
KR100531969B1 (ko) | 치환된 3-시아노 퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법 | |
AU763669B2 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
EP1315720B1 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
CN103664802B (zh) | 作为受体酪氨酸激酶抑制剂的喹唑啉类似物 | |
JP2002539199A (ja) | 二環式複素環化合物、その化合物を含む医薬組成物、及び製法 | |
KR20030024914A (ko) | 이환식 헤테로사이클, 당해 화합물을 함유하는 약제, 이의용도 및 이의 제조방법 | |
PT823900E (pt) | Derivados de quinazolina | |
HU211311A9 (en) | Quinazoline derivatives | |
WO2008112407A1 (en) | Spiro substituted compounds as angiogenesis inhibitors | |
JPH05208911A (ja) | 抗癌作用を有する医薬組成物、キナゾリン誘導体及びその製法 | |
KR20080016600A (ko) | 3-시아노-퀴놀린의 제조 방법 및 이에 의해 제조된 중간생성물 | |
JPH11504034A (ja) | キナゾリン誘導体 | |
AU2006249596A1 (en) | Methods of synthesizing 6-alkylaminoquinoline derivatives | |
JP2004517059A (ja) | 抗腫瘍剤用の4−置換キノリン類 | |
JP2003528880A (ja) | 三環系タンパクキナーゼ阻害薬 | |
BRPI0318503B1 (pt) | Quinolinas substituídas e composição farmacêutica compreendendo as mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |